Journal of Medicinal Chemistry p. 234 - 240 (1995)
Update date:2022-09-26
Topics:
Houlihan, William J.
Munder, Paul G.
Handley, Dean A.
Cheon, Seung H.
Parrino, Vincent A.
A series of 5-aryl-2,3-dihydroimidazo<2,1-a>isoquinolines previously reported to be platelet activating factor (PAF) receptor antagonist were evaluated for potential antitumor activity.Several compounds, such as the 5-(4'-tert-butylphenyl) (65), 5-<4'-(trimethylsilyl)phenyl> (69), and 5-(4'-cyclohexylphenyl) (71) analogs showed very good cytotoxicity against several tumor cell lines. 5-<4'-(Piperidinomethyl)phenyl>-2,3-dihydroimidazo<2,1-a>isoquinoline (SDZ 62-434, 53) was more effective on a milligram per kilogram basis than the clinical cytostatic agent edelfosine (1) in increasing survivors and decreasing tumor volume in the oral mouse Meth A fibrosarcoma assay.It was selected for further development and is currently in phase I clinical trials in cancer patients.
View MoreSuZhou Ascepion Pharmaceuticals, Inc.(expird)
Contact:0512-86881668
Address:Building C,68Xingqing Road,Suzhou,China.
Shenyang Mole pharmaceutical Technology Development Co.,Ltd
Contact:+86-24-31204918/13889278616
Address:No.44, wanliutang road, shenhe District of Shenyang
Contact:+86-532-80762375
Address:No. 6, Hongkong Middle Road, Qingdao, China
Contact:0091-265-2313036
Address:311, ATLANTIS HEIGHTS SARABHAI MAIN ROAD,VADIWADI ,VADODARA
Lanzhou huibang biological chemical technology Co., LTD
Contact:0931-7843964
Address:NO.2011,Yannan Road,Chengguan,
Doi:10.1021/jo00310a014
(1990)Doi:10.1016/j.chempr.2017.10.007
(2017)Doi:10.1021/acs.jmedchem.0c00566
(2020)Doi:10.1246/bcsj.59.1277
(1986)Doi:10.1016/j.ejmech.2011.01.051
(2011)Doi:10.1021/ja2026882
(2011)
